**2. Vascular adhesion protein-1 and hepatocellular cancer**

Unmixed lymphocytes travel continuously throughout the body in search of antigens. Blood-borne lymphocytes leave the circulation by binding to the endothelium of specialized postcapillary high endothelial venules (HEVs) in lymph nodes, move through the tissue stroma, and later return to the circulation via efferent lypmhatics 26. Elemental lymphocytes can freely circulate through both peripheral lymph nodes (PLNs) and mucosa-associated lymphatic tissues, which represent two functionally different re-circulatory systems. It has been known for some time that T cells immigrate and bind to PLN 2-5 times more frequently than B cells. On the contrary, B cells adhere 2-3 times more frequently than T cells to HEVs in mucosal lymphatic organs. When unmixed lymphocytes adhere to their related antigens, the migratory properties of the activated lymphocytes change dramatically. They no longer freely circulate through different lymphatic organs but instead selectively extravasate at sites of the original antigenic and in related lymphoid tissues 27.

Lymphocyte exchange between the circulation and tissues is essential for the appropriate function of the immune system. In the extravasation function, blood-borne cells make primary contacts with endothelial adhesion molecules, which may stimulate grappling, activation, entrenched binding, and finally transmigration 1, 27. The grappling cells can be

The VAP-1 molecule is a 170 kDa homodimeric glycoprotein that consists of two 90 kDa subunits that are held together by disulfide bonds 20. VAP-1 has a large extracellular domain, a single-pass transmembrane domain, and a short cytoplasmic cue 21. The molecule has ample sialic acid moieties that are required for its adhesive function, which was shown based on the inability of VAP-1 to mediate lymphocyte adhesion to desialylated vessels 20 .

Serum measurements of VAP-1 are performed by enzyme-linked immunosorbent assay22. A possible role for VAP-1 was shown in adhesion assays. VAP-1 may have a normal physiological role in maintaining the proadhesive status of PBLs toward endothelia since its concentration in normal individuals is within the range that is used in these adhesion

Some reports have shown that significantly elevated levels of VAP-1 were found in patients with liver diseases 22, 23. Patients had increased systemic circulation, and VAP-1 levels in these patients were higher, suggesting that VAP-1 could engender biological effects. It is interesting that patients with hepatocellular carcinoma had higher VAP-1 values than patients with inflammatory liver diseases, which agrees well with the finding of high VAP-1 expression in primary liver tumors but not in liver metastases 22-24. Other non-hepatic inflammatory diseases were not related to increased levels of VAP-1 23. An increase in VAP-1 levels is specific to particular inflammatory diseases. The specificity of increased VAP-1 levels for certain liver diseases (hepatocellular carcinoma) justifies further characterization

In conclusion, VAP-1 is present in the serum of healthy individuals at a level similar to those of most other soluble endothelial adhesion molecules 25. The concentration of VAP-1 is higher in certain liver diseases than the levels of other known circulating endothelial

Unmixed lymphocytes travel continuously throughout the body in search of antigens. Blood-borne lymphocytes leave the circulation by binding to the endothelium of specialized postcapillary high endothelial venules (HEVs) in lymph nodes, move through the tissue stroma, and later return to the circulation via efferent lypmhatics 26. Elemental lymphocytes can freely circulate through both peripheral lymph nodes (PLNs) and mucosa-associated lymphatic tissues, which represent two functionally different re-circulatory systems. It has been known for some time that T cells immigrate and bind to PLN 2-5 times more frequently than B cells. On the contrary, B cells adhere 2-3 times more frequently than T cells to HEVs in mucosal lymphatic organs. When unmixed lymphocytes adhere to their related antigens, the migratory properties of the activated lymphocytes change dramatically. They no longer freely circulate through different lymphatic organs but instead selectively extravasate at

Lymphocyte exchange between the circulation and tissues is essential for the appropriate function of the immune system. In the extravasation function, blood-borne cells make primary contacts with endothelial adhesion molecules, which may stimulate grappling, activation, entrenched binding, and finally transmigration 1, 27. The grappling cells can be

The leukocyte ligand for VAP-1 is presently unknown.

of the role of VAP-1 in the inflammatory activity of these diseases.

**2. Vascular adhesion protein-1 and hepatocellular cancer** 

sites of the original antigenic and in related lymphoid tissues 27.

experiments.

adhesion molecules 23, 25.

exposed to activating stimuli such as chemokines that can reinforce the integrin-dependent adhesion of leukocytes and migration through vessel walls using adhesion molecules from immunoglobulin and other super-families as well as local protease activity. Immune function is predicated on the continuous exchange of lymphocytes between the blood and tissue and is regulated by molecular interactions between the circulating lymphocytes and ligands on the surface of endothelial cells 28.

VAP-1 was described after monoclonal antibody (mAB) 1B2 immunoprecipitation, which gave a 170- to 180-kDa homodimeric sialoglycoprotein that was formed by two 90 kDa subunits, bound by disulfide bonds, with close sequence homology to the copper-dependent semicarbazide-sensitive amine oxidases (SSAO) 1, 20. Both the transmembrane and soluble forms of VAP-1 exhibit monoamine oxidase activity 29. A rabbit homolog of VAP-1 has been shown to function under in vivo conditions during the primary temporary interactions between endothelial and lymphoid cells 20. VAP-1 has a large extracellular domain, a singlepass transmembrane domain, and a short cytoplasmic cauda 20.

Soluble adhesion molecules may have definite and adverse physiological effects. They may function as inhibitors of cell to cell adhesion by competing with their membrane-bound forms.

Serum measurements of VAP-1 were performed by enzyme-linked immunosorbent assay (ELISA). Blood was drawn into serum tubes and allowed to clot for at least 30 min, centrifuged at 3000 rpm for 10 min and kept frozen at -70°C 22. Wells of microtiter plates were coated with 100 µl of the anti–VAP-1 mAb TK8-18 at 10 µg/ml in 0.1 M NaHCO3 buffer (pH 9.6), stored at 40Covernight, and then kept at 37°C for 1 h. The wells were washed 6 times with 0.1% Tween 20 in phosphate buffered saline (PBS) and then blocked by the addition of 200 µl of PBS containing 1% gelatin and 1% nonfat milk powder (blocking solution) for 45 min at room temperature to prevent nonspecific adsorption. After washing the wells 6 times with Tween/PBS, 175 µl of each serum sample was added to the wells, and the plates were left at room temperature for 1 h. The wells were then washed six times with Tween/PBS and incubated with 100 µl of the biotinylated anti–VAP-1 mAbTK8-14 or biotinylated control mAb Hermes-3 at room temperature for 1 h. After six washes with Tween/PBS, 100 µl of streptavidin–horseradish peroxidase was added to the wells, and the plates were allowed to incubate at room temperature again for 1 h. Thereafter, the plates were washed six times with Tween/PBS and finally developed with a chemoluminescence ELISA reagent (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. All serum samples were measured at 1:25 dilution. Each sample was measured in triplicate, and the anti–VAP-1 value was calculated by subtracting the mean background value of the negative control from the mean value of VAP-1 23.

Each assay included a titration of the quantified tonsil lysate; this titration was used to generate a standard curve. To obtain a protein milieu similar to the serum samples, tonsil lysate standards were diluted in blocking solution that contained as much VAP-1–depleted human serum as the test samples contained patient serum. Calculations of the amount of sVAP-1 in the serum samples were made by comparing the specific VAP-1 values with a standard curve of titrated tonsil lysate using a linear regression analysis 23.

The adhesive function of VAP-1 is important in optimal oligosaccharide modifications since desialylated VAP-1 does not bind to lymphocytes 30. The lymphocyte ligand of VAP-1 is

Vascular Adhesion Protein-1 and Hepatocellular Cancer 157

adhesion of lymphocytes to vascular endothelial cells on the periphery of primary liver tumors. This mechanism could increase the immune response at the tumor where other adhesion molecules involved in the multistep adhesion cascade are also elevated in primary liver tumors. The rise in VAP-1 expression is specific to liver tumors because other non-

VAP-1 expression occurs in the hepatic vascular bed 38, 39. This occurrence suggests that some of the elements of the adhesion cascade in the hepatic vascular bed differ from those in

VAP-1 mediated adhesion is consistent with the finding of VAP-1–dependent lymphocyte adhesion to rat peripheral lymph node endothelial cells transfected with human VAP-1 and with recent intravital studies where it has been shown to act as a brake for neutrophils in rabbit mesenteric blood vessels 39. The precise nature of the adhesion mediated by VAP-1 was unclear, although the total number of adherent cells was reduced with the inhibition of VAP-1, suggesting that its receptor is active at different points in the

The inhibition of adhesion by blockade of VAP-1 had a marked inhibitory effect on lymphocyte transendothelial migration that was independent of its capability to assist adhesion. This effect was specific for VAP-1. It has also been proposed that VAP-1 mediates

VAP-1 is a monoamine oxidase, and this functionality was demonstrated with soluble VAP-1 protein 40. Recent reports suggest that the adhesive and enzymatic functions of VAP-1 are closely linked. Some specific inhibitors block the enzymatic activity of VAP-1, and the specific semicarbazide-sensitive amine oxidase inhibitor (SSAO), semicarbazide, and a broad-acting monoamine oxidase inhibitor, hydroxylamine, both decreased lymphocyte adhesion and transmigration. The enzymatic activity of VAP-1 is thought to be important in

This effect was specific for hepatic endothelial cells that express VAP-1 since adhesion and transmigration of lymphocytes was observed. Other molecules have been shown to share adhesive and enzymatic properties, but VAP-1 is the only adhesion molecule with amino oxidase activity 23, 40. The active site of the SSAO in VAP-1 may mediate adhesion via interactions with immobilized amine residues on the lymphocyte surfaces 40. The fact that the inhibitors had a similar effect on transendothelial migration is the first demonstration of

The identification of VAP-1 as a new contact-initiating ligand suggests that it may be part of an optimal molecular pathway for regulating the specificity and multiplicity of the initial

VAP-1 may be a molecule that is template expressed in the liver tumor vasculature but down-regulated in some tumors during the growth of the malignancy or not up-regulated in some other tumors. Since VAP-1 clearly binds to the blood vessels of liver tumors, it is conceivable that the up-regulation of VAP-1 in liver tumors with a low level of VAP-1

expression may improve the treatment of hepatocellular carcinoma 20, 40, 41.

hepatic tumors are not associated with elevated levels of VAP-1.

post capillary venules.

adhesion cascade.

the transmigration of adherent leukocytes 28.

enzymatic regulation of this process.

steps of lymphocyte–endothelial cell interactions.

the adhesion of lymphocytes to VAP-1–transfected cells.

unknown whereas the enzymatic reaction takes place independently within the rotund buried catalytic center of the molecule 31.

VAP-1 is postulated as a mediator of adhesion of effector lymphocytes to tumor vasculature. It is an endothelial adhesion molecule that is up-regulated at inflammation sites and mediates lymphocyte binding to inflamed endothelium 23.

Similar to the membrane-bound endothelial VAP-1 1, circulating VAP-1 involves effusive sialic acid decorations (moieties). The finding of effusive sialic acid remnants in VAP-1 is especially noteworthy because the adhesive function of VAP-1 depends on its sialic acids 1. VAP-1 is a deeply sialylated molecule that might be functionally active.

The probable biological effects of VAP-1 could affect the expression or function of other adhesion molecules in vivo or in vitro in primary endothelial cells and in liver endothelial cells. These effects of VAP-1 on the synthesis of other adhesion molecules such as fucosyltransferases or sulfotransferases might contribute to the significantly rising capability of VAP-1 transfectants to effect lymphocyte accession.

VAP-1 mediates the leukocyte subtype-specific recognition of HEVs under nonstatic conditions in humans, and hence, it represents a previously unknown method of achieving selectivity of the leukocyte-endothelial interactions in the multistep adhesion cascade. VAP-1 is able to mediate the adhesion of PLN and HEV. Moreover, VAP-1 extends the role of carbohydrate-dependent lymphocyte–endothelial cell interactions 20.

VAP-1 mediates HEV binding of lymphocytes but not of monocytes. Adhesion of T and B cells was independent of VAP-1. VAP-1 mediated oligosaccharide-dependent adhesion to endothelial cells under non-static harvest conditions 20, implying that it is involved in the adhesion cascade.

Hepatic endothelial cells are lined by specialized endothelium that supports lymphocyte adhesion and recruitment in an optimal low-shear environment 31. Hepatic endothelium has a phenotype that is different from the endothelium of other vascular beds. In vivo hepatic endothelial cells express low levels of CD31 which are the most expansive entrapment receptors in other tissues 32. Human hepatic endothelial cells secrete the endothelial adhesion molecule VAP-1 33, which is major defective from non-inflamed vessels in extralymphoid organs 34. The ability of VAP-1 to mediate sialic acid-dependent adhesion suggests that it could have a particular function in the liver by mediating shear-dependent adhesion in the selectins 15. However, human liver endothelial cell behavior under conditions of shear stress is unknown.

VAP-1 on liver endothelium promotes lymphocyte adhesion under laminar shear stress but not in hepatic roaming in vivo 35; VAP-1 is a mediator of lymphocyte transendothelial migration, but the capability of VAP-1 to promote adhesion and transendothelial migration is blocked by specific inhibitors of its enzyme activity 35. Functional characterization of VAP-1 has not been conducted because the molecule is not expressed on the cell surface of human endothelial cell lines 22.

In some studies, rising levels of serum VAP-1 were found in patients with hepatocellular cancer 36, 37. These results suggest that increasing levels of VAP-1 contribute to the elevated

unknown whereas the enzymatic reaction takes place independently within the rotund

VAP-1 is postulated as a mediator of adhesion of effector lymphocytes to tumor vasculature. It is an endothelial adhesion molecule that is up-regulated at inflammation sites and

Similar to the membrane-bound endothelial VAP-1 1, circulating VAP-1 involves effusive sialic acid decorations (moieties). The finding of effusive sialic acid remnants in VAP-1 is especially noteworthy because the adhesive function of VAP-1 depends on its sialic acids 1.

The probable biological effects of VAP-1 could affect the expression or function of other adhesion molecules in vivo or in vitro in primary endothelial cells and in liver endothelial cells. These effects of VAP-1 on the synthesis of other adhesion molecules such as fucosyltransferases or sulfotransferases might contribute to the significantly rising capability

VAP-1 mediates the leukocyte subtype-specific recognition of HEVs under nonstatic conditions in humans, and hence, it represents a previously unknown method of achieving selectivity of the leukocyte-endothelial interactions in the multistep adhesion cascade. VAP-1 is able to mediate the adhesion of PLN and HEV. Moreover, VAP-1 extends the role of

VAP-1 mediates HEV binding of lymphocytes but not of monocytes. Adhesion of T and B cells was independent of VAP-1. VAP-1 mediated oligosaccharide-dependent adhesion to endothelial cells under non-static harvest conditions 20, implying that it is involved in the

Hepatic endothelial cells are lined by specialized endothelium that supports lymphocyte adhesion and recruitment in an optimal low-shear environment 31. Hepatic endothelium has a phenotype that is different from the endothelium of other vascular beds. In vivo hepatic endothelial cells express low levels of CD31 which are the most expansive entrapment receptors in other tissues 32. Human hepatic endothelial cells secrete the endothelial adhesion molecule VAP-1 33, which is major defective from non-inflamed vessels in extralymphoid organs 34. The ability of VAP-1 to mediate sialic acid-dependent adhesion suggests that it could have a particular function in the liver by mediating shear-dependent adhesion in the selectins 15. However, human liver endothelial cell behavior under

VAP-1 on liver endothelium promotes lymphocyte adhesion under laminar shear stress but not in hepatic roaming in vivo 35; VAP-1 is a mediator of lymphocyte transendothelial migration, but the capability of VAP-1 to promote adhesion and transendothelial migration is blocked by specific inhibitors of its enzyme activity 35. Functional characterization of VAP-1 has not been conducted because the molecule is not expressed on the cell surface of human

In some studies, rising levels of serum VAP-1 were found in patients with hepatocellular cancer 36, 37. These results suggest that increasing levels of VAP-1 contribute to the elevated

buried catalytic center of the molecule 31.

mediates lymphocyte binding to inflamed endothelium 23.

of VAP-1 transfectants to effect lymphocyte accession.

adhesion cascade.

conditions of shear stress is unknown.

endothelial cell lines 22.

VAP-1 is a deeply sialylated molecule that might be functionally active.

carbohydrate-dependent lymphocyte–endothelial cell interactions 20.

adhesion of lymphocytes to vascular endothelial cells on the periphery of primary liver tumors. This mechanism could increase the immune response at the tumor where other adhesion molecules involved in the multistep adhesion cascade are also elevated in primary liver tumors. The rise in VAP-1 expression is specific to liver tumors because other nonhepatic tumors are not associated with elevated levels of VAP-1.

VAP-1 expression occurs in the hepatic vascular bed 38, 39. This occurrence suggests that some of the elements of the adhesion cascade in the hepatic vascular bed differ from those in post capillary venules.

VAP-1 mediated adhesion is consistent with the finding of VAP-1–dependent lymphocyte adhesion to rat peripheral lymph node endothelial cells transfected with human VAP-1 and with recent intravital studies where it has been shown to act as a brake for neutrophils in rabbit mesenteric blood vessels 39. The precise nature of the adhesion mediated by VAP-1 was unclear, although the total number of adherent cells was reduced with the inhibition of VAP-1, suggesting that its receptor is active at different points in the adhesion cascade.

The inhibition of adhesion by blockade of VAP-1 had a marked inhibitory effect on lymphocyte transendothelial migration that was independent of its capability to assist adhesion. This effect was specific for VAP-1. It has also been proposed that VAP-1 mediates the transmigration of adherent leukocytes 28.

VAP-1 is a monoamine oxidase, and this functionality was demonstrated with soluble VAP-1 protein 40. Recent reports suggest that the adhesive and enzymatic functions of VAP-1 are closely linked. Some specific inhibitors block the enzymatic activity of VAP-1, and the specific semicarbazide-sensitive amine oxidase inhibitor (SSAO), semicarbazide, and a broad-acting monoamine oxidase inhibitor, hydroxylamine, both decreased lymphocyte adhesion and transmigration. The enzymatic activity of VAP-1 is thought to be important in the adhesion of lymphocytes to VAP-1–transfected cells.

This effect was specific for hepatic endothelial cells that express VAP-1 since adhesion and transmigration of lymphocytes was observed. Other molecules have been shown to share adhesive and enzymatic properties, but VAP-1 is the only adhesion molecule with amino oxidase activity 23, 40. The active site of the SSAO in VAP-1 may mediate adhesion via interactions with immobilized amine residues on the lymphocyte surfaces 40. The fact that the inhibitors had a similar effect on transendothelial migration is the first demonstration of enzymatic regulation of this process.

The identification of VAP-1 as a new contact-initiating ligand suggests that it may be part of an optimal molecular pathway for regulating the specificity and multiplicity of the initial steps of lymphocyte–endothelial cell interactions.

VAP-1 may be a molecule that is template expressed in the liver tumor vasculature but down-regulated in some tumors during the growth of the malignancy or not up-regulated in some other tumors. Since VAP-1 clearly binds to the blood vessels of liver tumors, it is conceivable that the up-regulation of VAP-1 in liver tumors with a low level of VAP-1 expression may improve the treatment of hepatocellular carcinoma 20, 40, 41.

Vascular Adhesion Protein-1 and Hepatocellular Cancer 159

[20] Salmi M, Jalkanen S. Human vascular adhesion protein (VAP-1) is a unique

[21] Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S. Cloning of vascular adhesion

[22] Kemk O, Sumer A, Kemk A, Itk V, Dulger AC, Purisa S, Tuzun S. Human vascular

[23] Kurkijarvi R, Adams DH, Leino R, Möttönen T, Jalkanen S, Salmi M. Circulation form

[24] Yoong KF, Hubscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support

[25] Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today

[26] Gowans JL, Knight EJ. The route re-circulation of lypmhocytes in rat. Proc R Soc Lond

[28] Salmi M, Jalkanen S. VAP-1: an adhesion and an enzyme. Trends Immunol 2001; 22:

[29] Salmi M, Tohka S, Berg EL, Butcher EC, Jalkanen J. Vascular adhesion protein-1

[31] Adams DH, Hubscher N, Fisher C, Williams A, Robinson M. Expression E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996; 24: 533. [32] Ley K, Tedder TF. Leukocyte interactions with vascular endothelium : new insights into selectin-mediated attachment and rolling. J Immunol 1995; 155: 525. [33] McNab G, Reeves L, Salmi M, Jalkanen S, et al. Vascular adhesion protein-1 supports

[34] Wong J, Johnston B, Lee D, et al. A minimal role for selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J Clin Invest 1997; 99: 2782. [35] Arvilommi AM, Salmi M, Jalkanen S. Organ-selective regulation of vascular adhesion

[36] Salmi M, Jalkanen S. A 90kDa endothelial cell molecule mediating lymphocyte binding

[37] Kukijarvi R, Yegutkin B, Gunson S, Jalkanen JS, Salmi M, Adams DH. Circulasting

oxidase activity in chronic liver disease. Gastroenterology 2000; 119: 1096. [38] Tohka S, Laukkanen, L, Jalkanen S, Salmi M. VAP-1 functions as a molecular brake

soluble vascular adhesion protein-1 accounts for the increased serum monoamine

during granulocyte rolling and mediates recruitment in vivo. FASEB J 2001; 15: 373.

vascular endothelium in human lymph nodes. J Exp Med 1997; 186: 589. [30] Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen J. Cloning of vascular adhesion

mediates lymphocyte subtype-specific, selectin-independent recognition of

protein-1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;

adhesion of T lymphocytes to hepatic endothelium : a mechanism for T cell

to endothelial cells. J Exp Med 1996; 183: 569.

fatty liver diseases. World J Surg Oncol 2010; 8: 83.

hepatocellular carcinoma. J Immunol 1998; 160: 3978.

[27] Butcher EJ. Lypmhocyte homing and homestosis. Science 1996; 272: 60-66.

recirculation to the liver? Gastroenterolgy 1996; 110: 522.

protein-1 expression in man. Eur J Immunol 1997; 27: 1794.

in humans. Science 1992; 257: 1407.

liver diseases. J Immunol 1998; 161: 1549-1557.

1998; 271: 500.

1993; 14: 506.

211-216.

188(1): 17-27.

Ser B 1964; 159: 257-282.

sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes

protein-1 (VAP-1) reveals a novel multifunctional adhesion molecule. J Exp Med

adhesion protein-1: Serum levels of hepatocellular carcinoma in non-alcoholic and

of human vascular adhesion protein-1: Increased serum levels in inflammatory

the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human

#### **3. References**


[1] Salmi M, Jalkanen JS. How do lymphocytes know where to go: current concepts and

[2] Butcher EC. Leukocyteo-endothelial cell recgnition: three steps to specificity and

[3] Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the

[4] Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068.

[6] Picker L, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing.

[7] Stoolman LM. Adhesion molecules controlling lymphocyte migration. Cell 1989; 56: 907. [8] Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial

[9] Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with garnulocytes: tethering and signaling molecules. Immunol Today 1992; 13: 99. [10] Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA,

[12] Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion

[13] Mehal ZW, Juedes AE, Crispe IN. Selective retention of activated CD8+ T cells by the

[14] Hamann A, Klugewitz K, Austrup F, Jablonski-Westrich D. Activation induces rapid

[15] Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE,

[16] Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen J, Adams DH. Vascular adhesion

[17] Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH, Chemokine and

[18] Salmi M, Adams DH, Jalkanen S. Lymphocyte trafficking in the intestine and liver. Am

[19] Jaeschke H, Smith CW. Cell adhesion and migration. III. Leukocyte adhesion and transmigration in the liver vascularite. Am J physiol 1997; 273: G1169.

and profound alterations in the trafficking of T cells. Eur J Immunol 2000; 30: 3207.

O'Farrely C. The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, and

molecul-1 mediates adhesion and trans migration of lymphocytes on human

chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J

organizing principle in regional immunity. J Exp Med 2000; 192: 761. [11] Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weismann IL,

Goodman SB, Genovese MC. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine expression of tissue specific chemokines as an

Hamman A, Butcher EC. Alpha-4 β7 integrin mediates binding to mucosal vascular

[5] Osborn L. Leukocyte adhesion to endothelium in inflammation. Cell 1990; 62: 3.

enigmas of lymphocyte homing. Adv Immunol 1997; 64: 139.

diversity. Cell 1991; 67: 1033.

multistep paradigm. Cell 1994; 76: 301.

Annu Rev Immunol 1992; 10: 561.

cells. Immunol Today 1992; 13: 106.

addressin MAdCAM-1. Cell 1993; 74: 185.

normal liver. J Immunol 1999; 163: 3202.

Immunol 1999; 163: 6236.

J Physiol 1998; 274: G1.

molecule for skin-homing T cells. Nature 1991; 349: 796.

Th0 cytokine secretion pattern. J Immunol 1999; 163: 2314.

hepatic endothelial cells. J Immunol 2002, 169: 983-992.

**3. References** 


**7** 

Yong Xu et al.\*

*P.R. China* 

**Tissue Factor Pathway Inhibitor-2 Inhibits** 

**Carcinoma Cells and is Inactivated in** 

**Human Hepatocellular Carcinoma** 

*Pingshan People's Hospital, Shenzhen, Guangdong* 

 **the Growth and Invasion of Hepatocellular** 

Human tissue factor pathway inhibitor-2 (TFPI-2) is an extracellular matrix-associated Kunitz-type serine proteinase inhibitor that inhibits the plasmin- and trypsin-mediated activation of matrix metalloproteinases and inhibits tumor progression, invasion and metastasis. Previous studies have shown that TFPI-2 is downregulated in the progression of various tumors. Here we aim to investigate the expression and function of TFPI-2 in hepatocellular carcinoma (HCC). *In situ* hybridization and immunohistochemical analyses revealed that the expression of TFPI-2 in hepatocarcinoma tissues was markedly lower than that in tumor-adjacent normal hepatic tissues. Restored expression of TFPI-2 in HepG2 cells inhibits cell proliferation and invasion. Taken together, our results suggest that TFPI-2 plays

tumor-suppression function and its inactivation may contribute to HCC.

**2. TFPI-2 expression in normal hepatic and hepatocarcinoma tissues** 

Human hepatocarcinoma tissues and tumor-adjacent normal hepatic tissues were obtained from HCC patients admitted to Shenzhen People's Hospital. They were stored frozen at -

Tumor specimens were fixed in formalin overnight and embedded in paraffin using standard procedures. Series sections (4um) were deparaffinized with xylene, rehydrated in a graded series of ethanol, and washed in PBS. Human TFPI-2 mRNA was detected using the

 Xiaolin Qin2, Jinjing Zhou2, Zhiguang Tu2, Xiao Bi3, Wuxian Li2, Xiaoqing Fan2 and Yi Zhang3 *1Pingshan People's Hospital, Shenzhen, Guangdong, P.R. China 2Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Chongqing Medical University,* 

*3The Second Clinical Medical College, Jinan University, Shenzhen People's Hospital, Guangdong, P.R. China*

**1. Introduction** 

**2.1 Tissue specimens** 

**2.2 In situ hybridization** 

*Chongqing, P.R. China* 

75C until use.

 \*

